GF Fermentec Unveils High-Speed Commercialization CDMO Platform at SynBioBeta 2026

GF Fermentec, a subsidiary of HLB Genex, unveiled its "High-Speed Commercialization CDMO Platform" at SynBioBeta 2026, the world’s largest synthetic biology conference, signaling its drive to enter the global market.

According to HLB Genex on May 8, GF Fermentec participated in SynBioBeta 2026, the world’s largest synthetic biology conference, held from May 4 to 7 (local time) in San Jose, California, USA. GF Fermentec promoted its core manufacturing infrastructure and began efforts in earnest to attract global clients. Dong-Eun Jang, Vice President and CTO of GF Fermentec, delivered a keynote speech titled "Future Expansion: Accelerating Enzyme Innovation and Bioproduct Commercialization."

GF Fermentec highlighted its tailored infrastructure that simultaneously meets the flexibility required for synthetic biology R&D and the stability needed for industrial-scale production. The company emphasized its systematic setup of pilot and commercial manufacturing lines ranging from 1L to 50,000L, boasting a total fermentation and purification infrastructure capacity of 160kL.

In particular, its data-driven real-time process control technology, which combines inline spectroscopic analysis and machine learning, was introduced as a core competitive advantage. This technology enables preemptive control of variables that may arise during fermentation, ensuring batch-to-batch consistency and guaranteeing perfect reproducibility of high-quality materials at commercial production scales as required by customers.

The company’s expertise in high-efficiency, ultra-high-purity downstream processing (DSP) following fermentation also attracted significant attention at the event. GF Fermentec is equipped to handle both aqueous and organic solvent-based processes, and with a wide array of facilities covering everything from supercritical extraction to microfiltration, ultrafiltration, freeze-drying, and spray drying, the company can manufacture even complex functional materials as customized final formulations for clients.

Through this conference, GF Fermentec aims to establish its "High-Speed Commercialization CDMO Platform" as a core competitive edge in the global market and to accelerate the development of long-term partnerships with promising collaborators. By showcasing its "Scaling Up Acceleration" capabilities, which dramatically reduce the time from research to mass production, the company is determined to solidify its position as a global leader in the next-generation bioproducts market.

This content was produced with the assistance of AI translation services.